An interventional study of HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy in Cervical Cancer, sponsored by The Greater Poland Cancer Centre. Active, not recruiting at 1 site in Poland. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by The Greater Poland Cancer Centre · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Uterine Cervical Neoplasms with a site in Poland — 6 open to participants now, 10 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Poland.
Among the 31 studies in Uterine Cervical Neoplasms with a site in Poland, this one is the 27th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2020, is one of 2 with no phase, and was the 17th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →6 of the 31 studies in Uterine Cervical Neoplasms with a site in Poland are open now. Recruiting first, the newest first:
Affidea Nu-med Center of Oncological DIagnostics and Therapy · Sites in Poland
Ages 18+
Affidea Nu-med Center of Oncological DIagnostics and Therapy · Sites in Poland
Ages 18+ · Women only
Merck Sharp & Dohme LLC · Sites in Poland, United States, Argentina and 26 more countries
Ages 18+ · Women only
Medical University of Silesia · Sites in Poland
Ages 18–85 · Women only
Daiichi Sankyo · Sites in Poland, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 9 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 256 across the 27 interventional studies, 412 across the 4 observational. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 31 have an industry lead sponsor. The 10 most frequent:
The Greater Poland Cancer Centre is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
The Greater Poland Cancer Centre has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Uterine Cervical Neoplasms with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
| NCT05081609Ascendis Pharma Oncology Division A/SA Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Uterine Cervical Neoplasms with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to describe changes in plasma HPV DNA levels in patients with locally advanced cervical cancer during radical radiochemotherapy (CRT) and to correlate changes with response to treatment. Monitoring of the response to treatment will also be assessed in FDG PET CT imaging.
Ninety-five per cent of cervical cancer cases are caused by persistent infections with carcinogenic HPVs. Locally advanced stage IB2 to IVA cervical cancers are treated with definitive chemoradiation therapy (CRT). Despite known clinical prognostic factors of poor treatment outcome such as advanced stage and positive nodal status, we still don't know predictors of relapse.
HPV status will be assessed in the neoplastic tissue and DNA from the blood serum of patients with cervical cancer will be isolated and analyzed by real-time PCR. Plasma HPV DNA would identify patients with residual disease after CRT due to persistent detectable HPV. This would earlier detect high risk patients who would benefit from adjuvant therapy.
While metabolic response in post - therapy FDG PET CT is predictive of survival, there is usually 3 months waiting period time needed to perform this imaging. This pilot study will provide preliminary estimates of the correlation between plasma HPV DNA level, PET finding and clinical outcome in polish cervical cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age Limits: more than 18Y confirmed squamous cell carcinoma, FIGO stage IB-IVA planned for radical radiochemotherapy (ECOG) performance status 0,1,2
Exclusion Criteria:
Patients who have received any anticancer treatment for their cervical cancer. (ECOG) performance status > 2 Other cervical cancer tumor histologies (e.g. small cell, serous) to 18FDG PET-CT Contraindication to radiochemotherapy Known pregnancy or lactating
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
Diagnostic Test: HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have: 1. FDG PET Scan before treatment and 3 months after treatment 2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status 3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy, 4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy.
local control
Time frame: 18 months
Response to treatment
Time frame: 6 months
Progression-free survival
Time frame: 18 months
Plasma HPV DNA levels
Time frame: Up to 3 months
Ran from Jun 2020 to primary completion in May 2022, 23 months.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 23 months is below that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Greater Poland Cancer Centre